Aquestive Therapeutics, Inc. (AQST)
收市後：
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, NJ 07059
United States
(908) 941-1900
https://www.aquestive.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 135
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Daniel Barber | CEO, President & Director | 1.06M | 無 | 1976 |
| Mr. A. Ernest Toth Jr. | Chief Financial Officer | 667.19k | 無 | 1959 |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 713.22k | 無 | 1956 |
| Ms. Cassie Jung | Senior Vice President of Operations | 無 | 無 | 1980 |
| Mr. Alexander Mark Schobel | Chief Innovation & Technology Officer | 672.69k | 無 | 1959 |
| Dr. Stephen Wargacki | Chief Science Officer | 無 | 無 | 1979 |
| Mr. Peter E. Boyd | Senior Vice President of IT, HR & Communications | 無 | 無 | 1966 |
| Dr. Gary H. Slatko M.D., MBA | Chief Medical Officer | 無 | 無 | 1958 |
| Dr. Carl N. Kraus M.D. | Chief Medical Officer | 無 | 無 | 1970 |
| Mr. Robert Charles Arnold | VP of Finance, Controller & Assistant Secretary | 無 | 無 | 無 |
描述
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
公司管治
截至 2024年5月1日 止，Aquestive Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：9；董事會：5；股東權利：8；現金賠償：7。
